Search for: "Bristol-Myers Squibb"
Results 161 - 180
of 863
Sort by Relevance
|
Sort by Date
12 Jan 2019, 10:12 am
On January 11, 2019, Congressman Peter Welch and Francis Rooney, members of Congress, wrote a letter to the Federal Trade Commission (“FTC”), urging the Commission to investigate Bristol-Myers Squibb’s (“BMS”) acquisition of Celgene. [read post]
4 Jan 2019, 9:16 pm
On December 5, 2018, the General Court ruled in favor of the European Commission in an action brought by Bristol-Myers Squibb Pharma (BMS) against the Commission and the European Medicines Agency (EMA) in the case, T‑329/16, read here. [read post]
3 Jan 2019, 12:01 pm
The acquisition brings together two of the largest drugmakers in the country, both of which are major players in biopharma, particularly oncology. [read post]
18 Dec 2018, 3:16 pm
Therefore, under the Supreme Court’s rulings in Daimler and Bristol-Myers Squibb, the defendant could be subject to personal jurisdiction in Massachusetts only if the conduct forming the basis for a plaintiff’s claim occurred in Massachusetts. [read post]
10 Dec 2018, 5:01 am
ZymoGenetics, after being purchased by Bristol-Myers Squibb, has been winding down their Seattle presence, first noted when they chose to not renew their lease of the historic Lake Union Steam Plant building in 2016. [read post]
7 Dec 2018, 2:28 pm
Bristol-Myers Squibb Co. v.Superior Court of Cal., 137 S.Ct. 1773, 1780 (2017). [read post]
1 Nov 2018, 9:38 am
Supreme Court’s decision in Bristol-Myers Squibb v. [read post]
27 Oct 2018, 10:58 am
Bristol-Myers Squibb, Co. [read post]
22 Oct 2018, 1:43 am
Indeed, both Upjohn and before Bristol-Myers Squibb and Others v Paranova (joined Cases C-427/93, 429/93 and 436/93) had indicated that “the requirement of artificial partitioning of the markets does not imply that the importer must demonstrate (emphasis added) that, by putting an identical product on the market in varying forms of packaging in different Member States, the trade mark proprietor deliberately sought to partition the markets between Member… [read post]
17 Oct 2018, 10:01 pm
Jones denied the plaintiff’s Disclosure Motion regarding two documents that defendant Bristol-Myers Squibb (BMS) claimed were privileged and inadvertently disclosed, stating that “[a]lthough BMS might not have followed the precise terms of the Protective Order”, “the one-day delay in sending the privilege log can charitably be described as a...Read the whole entry... [read post]
12 Oct 2018, 10:19 am
Freshbev LLC, 322 F.Supp.3d 330 (E.D.N.Y. 2018)Campbell bought several bottles of Freshbev juices at Whole Foods, allegedly relying on misrepresentations (1) that the juices were unpasteurized; (2) that the juices were cold-pressed; (3) that the juices were fresh; and (4) that the Cranberry Apple juice had more cranberry juice than apple juice.Initially, the court declined to resolve at this stage whether Bristol–Myers Squibb Co. v. [read post]
1 Oct 2018, 2:24 am
The drug was brought into the U.S. market by Otsuka America and Bristol-Myers Squibb in 2002.... [read post]
17 Sep 2018, 2:59 am
ArsTechnica] “Prosecutors Are Said to Issue Subpoenas Over Pelvic-Mesh Surgery Financing” [Matthew Goldstein and Jessica Silver-Greenberg, New York Times, earlier and more] Federal courts split on whether SCOTUS’s Bristol-Myers Squibb limits on personal jurisdiction apply to class actions [Bradley Arent, Akin Gump, Carlton Fields] Tags: arbitration, class actions, deep pocket, litigation finance, opioids, Texas [read post]
28 Aug 2018, 12:16 am
Although fact-specific, this case sets a threshold as to actions which would not constitute the repackaging of products (whilst Bristol-Myers Squibb and Boehringer Ingelheim set out actions which would). [read post]
23 Aug 2018, 3:00 am
The court provided a detailed summary of the current status of the law pertaining to personal jurisdiction based upon a review of several notable United States Supreme Court Opinions, the most recent of which was in the case of Bristol-Myers Squibb Co. v. [read post]
12 Jun 2018, 6:56 am
The agency’s argument that the regulation leaves the decision up to the employer was unavailing, the court explained, under the competitor standing doctrine and had already been rejected in earlier cases, such as Bristol-Myers Squibb Co. v. [read post]
11 Jun 2018, 8:00 am
Supreme Court in Bristol-Myers Squibb rejected such an argument. [read post]
9 Jun 2018, 8:58 pm
Paul Golian of Bristol-Myers Squibb Company, Ali Salimi of the U.S. [read post]
15 May 2018, 8:29 am
The District Court has ordered the defendants, Bristol-Myers Squibb Co., and Otsuka Pharmaceutical Co. [read post]
15 May 2018, 8:29 am
The District Court has ordered the defendants, Bristol-Myers Squibb Co., and Otsuka Pharmaceutical Co. [read post]
